Annexon says tanruprubart shows rapid strength gains in first 10 GBS FORWARD study patients

ANNX•2026-08-06

Early FORWARD results in Guillain-Barré syndrome

Annexon reported early FORWARD study results in Guillain-Barré syndrome, showing rapid functional improvement in all treated patients within about one week.

Patients showed quicker strength and mobility gains than typically expected, including faster recovery in severe cases requiring intensive support.

Safety was broadly consistent with prior experience, with adverse events mainly tied to the underlying disease or its complications.

Additional FORWARD data will be presented at upcoming medical conferences, supporting a planned BLA submission targeted for Q4 2026.

Tanruprubart remains under review by the European Medicines Agency.

Sources

Annexon says tanruprubart shows rapid strength gains in first 10 GBS FORWARD study patients

Publicnow

Annexon says tanruprubart shows rapid strength gains in first 10 GBS FORWARD study patients

Early FORWARD results in Guillain-Barré syndrome

Related News

AquaBounty expands Pioneer Ohio strategic review to target power and energy infrastructure development opportunities

Sonoma Pharma FY27 Q1 net loss narrows 73.41% to USD 330,000; revenue rises 60% to USD 6.41 million

Scholar Rock files for up to $200 million at-the-market stock offering

Sources

Annexon says tanruprubart shows rapid strength gains in first 10 GBS FORWARD study patients

Bleichroeder Acquisition Corp. II sets extraordinary shareholder meeting on Pasqal deal

HCA Healthcare names Michael Schlosser chief clinical officer effective Sept. 1